NCT04443036Unknown不适用
Albumin-bound Paclitaxel Combined With Toripalimab as First-line/Second-line Treatment of Local Advanced or Metastatic Gastric or Gastroesophageal Junction Carcinoma: A Prospective, Open-label, Single-arm Phase II Clinical Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This study is to evaluate the efficacy and safety of Albumin-bound paclitaxel combined with Toripalimab as first-line/second-line treatment of local advanced or metastatic gastric or gastroesophageal junction carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age:18-70 years old, female or male.
- •Histopathologically diagnosed local advanced or metastatic gastric or gastroesophageal junction carcinoma, HER2 negative.
- •At least one measurable lesion according to RECIST 1.
- •≤1 prior line. adjuvant/neoadjuvant therapy is allowed, adjuvant/neoadjuvant therapy is considered as the first-line treatment for advanced diseases, if recurrence occurs during the treatment or within 6 months after the last treatment. prior chemotherapy combined with targeted therapy is allowed.
- •ECOG performance status of 0 or
- •Adequate organ and bone marrow function: ANC≥1.5×109/L, PLT≥90×109/L, HGB≥90g/L,TBil≤1.5ULN, ALT≤2.5ULN, AST≤2.5ULN, Serum Cr≤1ULN, endogenous creatinine clearance>60ml/min (Cockcroft-Gault formula).
- •The international normalized ratio (INR) ≤ 1.5 and some prothrombin time (PPT or APTT) ≤ 1.5ULN within 7 days before enrollment.
- •Expected survival≥3 months.
- •Signed informed consent (ICF) before enrollment.
- •Women of childbearing age must undergo a pregnancy test within 7 days prior to enrollment and have a negative result and are willing to use effective and reliable contraceptive methods during and 6 months after the last treatment.
排除标准
- •History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins, or known allergic to any component of Toripalimab or any component of Albumin Bound paclitaxel.
- •severe hypersensitivity after previous administration of monoclonal antibody.
- •≥1 prior line therapy after progression.
- •Prior therapy with PD-1、PD-L1/L2、CTLA-4 antibody, or any other immunotherapy.
- •A history of organ transplantation.
- •Any other malignancy within 5 years excluding healed Basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of cervical or breast.
- •Received anti-tumor vaccine or other immune-stimulating agents (interferon, interleukin, thymosin, immuno cell therapy, etc.) within 1 month before the first treatment.
- •Symptomatic central nervous system metastases.
- •Acute or chronic Active hepatitis B or hepatitis C.
- •Interstitial pneumonia, pneumoconiosis, drug-induced pneumonia, pulmonary fibrosis, severely impaired lung function and other pulmonary diseases.
- •Active tuberculosis, receiving anti-TB treatment or have received anti-TB treatment within 1 year prior to first treatment.
- •Human immunodeficiency virus (HIV) infection（HIV antibody positive）, or known syphilis infection.
- •Severe uncontrolled disease, non-metastatic systemic disease, active or poor clinical control infection.
- •Patients with autoimmune diseases or abnormal immune system.
- •Treatment with immunosuppressive medications within 4 weeks prior to enrollment. Nasal spray, inhalation, or other ways of topical corticosteroids or systemic corticosteroids at physiologic doses （not to exceed 10 mg/day of prednisone or its equivalent Steroids）are not included.
- •Expected to require any other form of antitumor therapy while on study (including maintenance therapy with any other drugs for gastric or gastroesophageal junction carcinoma、radiotherapy and/or surgical resection)
- •Received major surgery or radiation therapy of > 30 Gy not to chest within 4 weeks of the first treatment, or radiation therapy of > 30 Gy to chest within 24 weeks of the first treatment,or radiation therapy of < 30 Gy to chest within 2 weeks of the first treatment, and had not recovered from the toxicity and/or complications of the most recent prior chemotherapy to Grade 1 or less (except alopecia or fatigue).
- •Poorly Controlled Diabetes（fasting blood-glucose ≥CTCAE grade 2）.
- •Clinically significant thyroid dysfunction and can't maintain thyroid hormone levels in the normal range with drugs.
- •Use of any live vaccines within 4 weeks before enrollment.
- •Pregnant or lactating subjects.
- •Participated in any other drug clinical study within 4 weeks before the enrollment.
- •Any other disease、metabolic disorders、Physical examination or laboratory abnormalities that might result in contraindications in the use of experimental drugs or affect the reliability of the study, or Puts patients at high risk.
- •The investigator believes are not suitable for participating in the study.
研究组 & 干预措施
Albumin-bound Paclitaxel Combined With Toripalimab
Experimental
- Albumin-bound Paclitaxel：125mg/m2 IV d1、8，Q3W
- Toripalimab：240 mg，IV d1，Q3W
- until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration of Toripalimab is 24 months
干预措施: Albumin-Bound Paclitaxel (Drug)
Albumin-bound Paclitaxel Combined With Toripalimab
Experimental
- Albumin-bound Paclitaxel：125mg/m2 IV d1、8，Q3W
- Toripalimab：240 mg，IV d1，Q3W
- until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration of Toripalimab is 24 months
干预措施: Toripalimab (Drug)
结局指标
主要结局
PFS
时间窗: up to 24 months
* Progression-Free Survival * Defined as the time from first dose of study medication to the first documented disease progression per RECIST version 1.1，or death from any cause, whichever occurred first
次要结局
- ORR(up to 24 months)
- DCR(up to 24 months)
- OS(up to 24 months)
- Change in Quality of Life(QoL)：measured by EORTC QLQ-C30 questionnaire(up to 24 months)
- Adverse events(up to 24 months)
研究者
Yunpeng Liu
Director of Department of Medical Oncology
China Medical University, China
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction AdenocarcinomaGastric/Gastroesophageal Junction AdenocarcinomaNCT06415669The First Affiliated Hospital of Xiamen University30
Unknown
2 期
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st ChemotherapySmall Cell Lung CancerNCT04698941Shanghai Pulmonary Hospital, Shanghai, China40
招募中
4 期
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast CancerBreast CancerNCT04136782Shengjing Hospital110
已完成
1 期
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma PatientsInduction ChemotherapyProgrammed Cell Death 1 InhibitorInductive TherapyOral CancerNCT04473716Shanghai Jiao Tong University School of Medicine20
撤回
不适用
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBCTriple Negative Breast CancerNCT04067102Hebei Medical University Fourth Hospital